Literature DB >> 19632069

Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes.

Nelson N Stone1, Richard G Stock, Jamie A Cesaretti, Pam Unger.   

Abstract

PURPOSE: To determine factors that influence local control and systemic relapse in patients undergoing permanent prostate brachytherapy (PPB). METHODS AND MATERIALS: A total of 584 patients receiving PPB alone or PPB with external beam radiation therapy (19.5%) agreed to undergo prostate biopsy (PB) at 2 years postimplantion and yearly if results were positive or if the prostate-specific antigen (PSA) level increased. Short-term hormone therapy was used with 280 (47.9%) patients. Radiation doses were converted to biologically effective doses (BED) (using alpha/beta = 2). Comparisons were made by chi-square analysis and linear regression. Survival was determined by the Kaplan-Meier method.
RESULTS: The median PSA concentration was 7.1 ng/ml, and the median follow-up period was 7.1 years. PB results were positive for 48/584 (8.2%) patients. Positive biopsy results by BED group were as follows: 22/121 (18.2%) patients received a BED of < or =150 Gy; 15/244 (6.1%) patients received >150 to 200 Gy; and 6/193 (3.1%; p < 0.001) patients received >200 Gy. Significant associations of positive PB results by risk group were low-risk group BED (p = 0.019), intermediate-risk group hormone therapy (p = 0.011) and BED (p = 0.040), and high-risk group BED (p = 0.004). Biochemical freedom from failure rate at 7 years was 82.7%. Biochemical freedom from failure rate by PB result was 84.7% for negative results vs. 59.2% for positive results (p < 0.001). Cox regression analysis revealed significant associations with BED (p = 0.038) and PB results (p = 0.002) in low-risk patients, with BED (p = 0.003) in intermediate-risk patients, and with Gleason score (p = 0.006), PSA level (p < 0.001), and PB result (p = 0.038) in high-risk patients. Fifty-three (9.1%) patients died, of which eight deaths were due to prostate cancer. Cause-specific survival was 99.2% for negative PB results vs. 87.6% for positive PB results (p < 0.001).
CONCLUSIONS: Higher radiation doses are required to achieve local control following PPB. A BED of >200 Gy with an alpha/beta ratio of 2 yields 96.9% local control rate. Failure to establish local control impacts survival. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632069     DOI: 10.1016/j.ijrobp.2009.01.078

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

1.  Treatment of localised prostate cancer with radiation therapy: evidence versus opinion.

Authors:  Ferran Guedea; Alfredo Ramos; Ismael Herruzo; José Antonio Sánchez Calzado; Jorge Contreras; Jesús Romero; Jordi Craven-Bartle; Patricia Willisch; José Luis López Torrecilla; Xavier Maldonado; Gemma Sancho; Almudena Zapatero; Montserrat Ferrer; Yolanda Pardo; Pablo Fernández; Alfonso Mariño; Asunción Hervás; Víctor Macís; Ana Boladeras; Ferran Ferrer; Brian J Davis
Journal:  Clin Transl Oncol       Date:  2010-05       Impact factor: 3.405

2.  Comparing CTVs for permanent prostate brachytherapy.

Authors:  C A Oton; L Blanco; L F Oton; S Moral
Journal:  Clin Transl Oncol       Date:  2014-10-29       Impact factor: 3.405

Review 3.  American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.

Authors:  M Keyes; G Merrick; S J Frank; P Grimm; M J Zelefsky
Journal:  Brachytherapy       Date:  2017-01-16       Impact factor: 2.362

4.  Ischemic proctitis after low-dose-rate brachytherapy using hydrogel spacer for prostate cancer.

Authors:  Ren Toriumi; Hiroshi Yaegashi; Takayuki Sakurai; Shigeyuki Takamatsu; Kazuyoshi Shigehara; Kouji Izumi; Yoshifumi Kadono; Atsushi Mizokami
Journal:  IJU Case Rep       Date:  2022-04-12

5.  Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer.

Authors:  Hideyasu Tsumura; Nobumichi Tanaka; Tomohiko Oguchi; Takuya Owari; Yasushi Nakai; Isao Asakawa; Kazuyoshi Iijima; Haruaki Kato; Iwao Hashida; Ken-Ichi Tabata; Takefumi Satoh; Hiromichi Ishiyama
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

6.  Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival.

Authors:  Kazuto Ito; Shiro Saito; Atsunori Yorozu; Shinsuke Kojima; Takashi Kikuchi; Satoshi Higashide; Manabu Aoki; Hirofumi Koga; Takefumi Satoh; Toshio Ohashi; Katsumasa Nakamura; Norihisa Katayama; Nobumichi Tanaka; Masahiro Nakano; Naoyuki Shigematsu; Takushi Dokiya; Masanori Fukushima
Journal:  Int J Clin Oncol       Date:  2018-06-22       Impact factor: 3.402

7.  Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial.

Authors:  Hiroyuki Konaka; Shin Egawa; Shiro Saito; Atsunori Yorozu; Hiroyuki Takahashi; Keiko Miyakoda; Masanori Fukushima; Takushi Dokiya; Hidetoshi Yamanaka; Nelson N Stone; Mikio Namiki
Journal:  BMC Cancer       Date:  2012-03-22       Impact factor: 4.430

8.  Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect?

Authors:  Alan J Katz; Michael Santoro; Richard Ashley; Ferdinand Diblasio
Journal:  Front Oncol       Date:  2011-12-05       Impact factor: 6.244

9.  Risk factors for rectal bleeding associated with I-125 brachytherapy for prostate cancer.

Authors:  Kosaku Harada; Hitoshi Ishikawa; Yoshitaka Saito; Soken Nakamoto; Hidemasa Kawamura; Masaru Wakatsuki; Toru Etsunaga; Yutaka Takezawa; Mikio Kobayashi; Takashi Nakano
Journal:  J Radiat Res       Date:  2012-08-01       Impact factor: 2.724

10.  The phylogeny of permanent prostate brachytherapy.

Authors:  Jesse N Aronowitz; Mark J Rivard
Journal:  J Contemp Brachytherapy       Date:  2013-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.